SLDB实时信号 | 通过Getagraph.com最大化利润

出售 108047 min ago

@ $8.00

发出时间: 14 Feb 2024 @ 22:30

回报率: 10.50%

上一信号: Feb 13 - 22:30

上一信号: 购买

回报率: 4.30 %

Live Chart Being Loaded With Signals

Commentary (29 Apr 2024 @ 23:10):

Stats
今日成交量	28 563.00
平均成交量	267 917
市值	333.77M
EPS	$0 ( 2024-03-28 )
下一个收益日期	( $-0.570 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.830
ATR14	$0.0370 (0.42%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-03	Smith Ian F	Buy	3 256	Common Stock
2024-04-03	Smith Ian F	Sell	3 256	Restricted Stock Units
2024-02-13	Hanrahan Jessie	Buy	65 000	Employee Stock Option (Right to Buy)
2024-02-13	Hanrahan Jessie	Buy	32 500	Restricted Stock Units
2024-02-13	Cumbo Alexander	Buy	240 250	Employee Stock Option (Right to Buy)

INSIDER POWER
95.48
Last 96 transactions
Buy: 8 088 873 \| Sell: 207 617

音量相关性

長: -0.07 (neutral)

短: 0.07 (neutral)

Signal:(31.838) Neutral

Solid Biosciences Inc 相关性

10 最正相关
CIZN	0.814

10 最负相关
CATB	-0.823

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Solid Biosciences Inc 相关性 - 货币/商品

-0.12
( neutral )

-0.18
( neutral )

0.00
( neutral )

-0.01
( neutral )

0.90
( strong )

0.09
( neutral )

Solid Biosciences Inc 财务报表

Annual	2023
营收:	$0
毛利润:	$-2.58M (0.00 %)
EPS:	$-4.83

FY	2023
营收:	$0
毛利润:	$-2.58M (0.00 %)
EPS:	$-4.83

FY	2022
营收:	$8.09M
毛利润:	$5.69M (70.25 %)
EPS:	$-7.70

FY	2021
营收:	$13.62M
毛利润:	$0.00 (0.00 %)
EPS:	$-10.14

Financial Reports:

No articles found.

Solid Biosciences Inc

Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy. It also engages in developing of platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one vector, as well as novel capsids. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.